Phase 3 primary completion: Pembrolizumab (MK-3475) with chemoradiotherapy in MIBC (KEYNOTE-992).
FDA catalyst calendar
Confirmed PDUFA dates, advisory committees and Phase 3 readouts. Every entry links to its primary source.
1 events · Clear filters
November 2026 1
- Nov2026
Merck Sharp & Dohme LLC — Pembrolizumab